ARQT vs XLK
Arcutis Biotherapeutics Inc (ARQT) versus Technology Select Sector SPDR® Fund (XLK) — a side-by-side from cached financials, not a winner call.
Arcutis Biotherapeutics Inc (ARQT) is a biotechnology company listed on US.
Technology Select Sector SPDR® Fund (XLK) common stock listed on US.
Latest reported ARQT revenue for 2026-06-30 was $235.3M. Net income was $3.7M. ARQT currently screens at market cap $1.64B.
XLK does not have a complete income-statement cache yet.
ARQT currently screens at market cap $1.64B. XLK currently screens at market cap $0.
Not investment advice. Open the ARQT and XLK stock pages for the full models.
Not investment advice.